In 1992 the discovery of the first endogenous ligand of cannabinoid receptors, anandamide, provided conclusive support to the hypothesis that an ''endogenous cannabinoid regulatory system'' exists in mammalian nervous tissue. Anandamide (N-arachidonoyl-ethanolamine) was the first of a series of long-chain fatty acid derivatives, including two other polyunsaturated N-acylethanolamines and 2-arachidonoyl-glycerol, found to exert cannabimimetic properties in either central or peripheral tissues. Here we review the current knowledge on the biochemical bases of the formation and inactivation of endogenous cannabinoid ligands as well as of their interaction with cannabinoid receptor subtypes.
INTRODUCTION
The discovery, cloning, and molecular characterization, between 1988 and 1990, of the brain cannabinoid receptor, later named CB 1 (1, 2), and the more recent discovery of a ''peripheral,'' CB 2 subtype of cannabinoid receptors in the spleen and immune cells (3), explained several of the pharmacological actions exerted by ⌬ 9 -tetrahydrocannabinol (THC) or synthetic cannabimimetics in both the CNS and peripheral tissues. These important breakthroughs, however, would have merely added two new members to the family of orphan receptors had not endogenous substances, capable of functionally activating these two receptors, been isolated shortly afterward. The putative endogenous ligands of cannabinoid receptors discovered to date are all lipid derivatives and not peptides, as was the case for the receptors of another plant-derived drug, morphine. However, if one considers the high lipophilicity of the psychoactive cannabinoids, it is not surprising that anandamide, the first endogenous cannabinoid receptor ligand to have been identified and characterized (4), is a non-water-soluble substance. Although there have been some reports in the brain of functionally active peptide-like ligands for CB 1 receptors (5-7), their structure has not yet been elucidated. By contrast, following the discovery of anandamide, other lipophilic molecules, i.e., amides or esters of long-chain fatty acids (Fig. 1) , have been shown to exhibit some cannabimimetic properties both in vitro and in vivo and, in some cases, through more than one mechanism of action. Here we review the discovery of these compounds, the chemical bases of their pharmacological actions, the pathways proposed for their biosynthesis and inactivation, and the possible ways of regulating these pathways in order to modulate the levels of endogenous cannabimimetic ligands for pharmacological and therapeutical purposes. In analogy with the nomenclature for the ''endorphins'' (morphine within) we shall refer to the endogenous ligands of cannabinoid receptors as ''endocannabinoids'' (cannabinoids within).
